Kelly CRISPR & Gene Editing Technology ETF (XDNA)
| Assets | $1.44M |
| NAV | $14.40 |
| Expense Ratio | n/a |
| PE Ratio | n/a |
| Shares Out | 100,000 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| 1-Year Return | +1.56% |
| Volume | 462 |
| Open | 14.99 |
| Previous Close | 14.42 |
| Day's Range | 14.99 - 14.99 |
| 52-Week Low | 13.86 |
| 52-Week High | 13.86 |
| Beta | n/a |
| Holdings | 0 |
| Inception Date | Jan 12, 2022 |
About XDNA
Kelly Strategic ETF Trust - Kelly CRISPR & Gene Editing Technology ETF is an exchange traded fund launched and managed by Kelly Strategic Management, LLC. The fund is co-managed by Penserra Capital Management, LLC. It invests in public equity markets of global developed markets region. The fund invests in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences, biotechnology, gene research and development, rDNA pharmaceuticals, CRISPR and gene editing technology, gene editing development solutions and gene editing sequencing solutions sectors. It invests in growth and value stocks of companies across diversified market capitalization. The fund seeks to track the performance of the Strategic CRISPR & Gene Editing Technology Index, by using full replication technique. Kelly Strategic ETF Trust - Kelly CRISPR & Gene Editing Technology ETF is domiciled in the United States.
News
Kelly Debuts With Thematic ETFs
The first-time issuer started off as an index provider.
Kelly ETFs Launches Debut Funds
Kelly ETFs, a new exchange traded fund issuer, has announced the launch of two new real estate-focused ETFs that begin trading on the New York Stock Exchange today, and one biotech ETF that trades on Na...
ETF Industry Leader Kevin Kelly Launches New Business, Introduces Cutting-Edge Suite of ETFs
DENVER--(BUSINESS WIRE)---- $HOTL--ETF Industry Leader Kevin Kelly Launches New Business, Introduces Cutting-Edge Suite of ETFs